MiRNAs Evaluate the Prognosis of Sepsis (METPS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by Chinese PLA General Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT01207531
First received: September 17, 2010
Last updated: September 22, 2010
Last verified: September 2010
  Purpose

Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to screen several miRNA by microarray which evaluate the sepsis prognosis in order to be a new target for the treatment of sepsis.


Condition
Sepsis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study

Resource links provided by NLM:


Further study details as provided by Chinese PLA General Hospital:

Primary Outcome Measures:
  • all cause mortality [ Time Frame: 28days after admited in ICU ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

human serum


Estimated Enrollment: 100
Study Start Date: July 2010
Estimated Study Completion Date: April 2011
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Survival Group
Death group

Detailed Description:

The study is a non-intervention, prospective observational study. Purpose of this sudy is to screening several miRNAs by microarray which can evaluate the prognosis of sepsis . We will collect serum samples from patients with sepsis in SICU, RICU and EICU of 301 Hospital since September 2009 , and then use the chip and qRT-PCR to Screen miRNAs which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

within 24 hours after admited in ICU

Criteria

Inclusion Criteria:

  • Clinical diagnosis of sepsis
  • Patients who agree with the study

Exclusion Criteria:

  • Aged <18 years;
  • Into the group who died within 24 hours;
  • Agranulocytosis (<0.5 × 109 / L);
  • Combined HIV infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01207531

Contacts
Contact: Huijuan Wang, master +86 13466791738 wanghuijuan301@gmail.com

Locations
China, Beijing
Chinese PLA General Hospital Recruiting
Beijing, Beijing, China, 100853
Sponsors and Collaborators
Chinese PLA General Hospital
Investigators
Study Director: Lixin Xie, Doctor Pneumology Department of chinese PLA General Hospital
  More Information

No publications provided by Chinese PLA General Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Lixin Xie, Pneumology Department of Chinese PLA General Hospital
ClinicalTrials.gov Identifier: NCT01207531     History of Changes
Other Study ID Numbers: 301PLAGH-2010915
Study First Received: September 17, 2010
Last Updated: September 22, 2010
Health Authority: China: Ethics Committee

Keywords provided by Chinese PLA General Hospital:
sepsis
miRNA

Additional relevant MeSH terms:
Sepsis
Toxemia
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on July 23, 2014